Journal
EPILEPSY CURRENTS
Volume 12, Issue 1, Pages 8-12Publisher
AMER EPILEPSY SOCIETY
DOI: 10.5698/1535-7511-12.1.8
Keywords
-
Categories
Funding
- MRC [G1000417] Funding Source: UKRI
- Medical Research Council [G1000417] Funding Source: Medline
- Medical Research Council [G1000417] Funding Source: researchfish
Ask authors/readers for more resources
Emerging data from experimental epilepsy models and resected human brain tissue support the proposed involvement of innate immune system activation and consequent inflammation in epilepsy. Key mediators of this process include interleukin-1 beta, high-mobility group box protein 1 (HMGB1), and Toll-like receptor (TLR) signaling. These recent findings constitute the basis for a novel avenue of drug development in epilepsy, one that is not only distinct from previous approaches but uniquely based on sound neurobiological evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available